Jin-Rong Qu

A Correction on Integration of multiparametric MRI and clinical indicators to predict response to immune-targeted therapy in patients with advanced hepatocellular carcinoma By Han S, Meng F, Wang L, Gao P, Zhang H and Qu J (2026). Front. Oncol. 16:1689963. doi: 10.3389/fonc.2026.1689963 The funder “Henan Province Central Plains Talent Program (Nurturing talent Series) (No. RS0011)” was erroneously omitted. The original version of this article has been updated.

Introduction Hepatocellular carcinoma (HCC), the most prevalent primary malignant tumor of the liver, continues to pose significant challenges in clinical diagnosis and management. Epidemiological data indicate that approximately 50% of patients with HCC in China are diagnosed at an intermediate or advanced stage, thereby missing the window for curative surgical intervention (1–3). As a result, systemic therapy becomes the primary treatment option for this patient population.

Introduction Gastric cancer (GC) has ranked fifth globally in both incidence and mortality as of 2022 (1). The TNM staging system serves as the cornerstone for GC assessment and treatment decisions in clinical practice (2). Importantly, N staging directly determines the extent of intraoperative lymph node dissection (3). Sentinel lymph nodes (SLNs), defined as the first nodes receiving tumor lymphatic drainage and serving as the initial metastatic site, may be crucial for N staging evaluation (4).